1 paper5 findings
Risk reclassification
upin humans1
Visceral adiposity improves risk reclassification in humans (NRI 0.48 (95% CI: 0.35–0.61)).
“NRI for ASCVD was 0.37 (95% CI: 0.30–0.33), for HF was 0.48 (95% CI: 0.35–0.61), and for total CVD was 0.37 (95% CI: 0.28–0.46)”
Humansn = 38,373
Evaluation of the PREVENT Risk Assessment Tool and Visceral Adiposity: Insights from the UK Biobank
AHA Scientific Sessions 2025 abstract3 Nov 2025
Discrimination
no changein humans1
Visceral adiposity has no effect on discrimination in humans (C-statistic 0.731 vs. 0.729, p = 0.85).
“Adding VAT to the PREVENT model did not significantly improve discrimination for ASCVD (C-statistic 0.731 vs. 0.729, p = 0.85), nor for HF or total CVD.”
Humansn = 38,373
Evaluation of the PREVENT Risk Assessment Tool and Visceral Adiposity: Insights from the UK Biobank
AHA Scientific Sessions 2025 abstract3 Nov 2025
Cardiovascular disease
upin humans1HR 1.38
Visceral adiposity raises the risk of cardiovascular disease in humans (HR: 1.38, 95% CI: 1.23–1.55).
“and total CVD (HR: 1.38, 95% CI: 1.23–1.55) adjusting for age and sex”
Humansadjusting for age and sexvisceral adipose tissuen = 38,373
Evaluation of the PREVENT Risk Assessment Tool and Visceral Adiposity: Insights from the UK Biobank
AHA Scientific Sessions 2025 abstract3 Nov 2025
Heart failure
upin humans1HR 1.55
Visceral adiposity raises the risk of heart failure in humans (HR: 1.55, 95% CI: 1.27–1.89).
“heart failure (HR: 1.55, 95% CI: 1.27–1.89)”
Humansadjusting for age and sexvisceral adipose tissuen = 38,373
Evaluation of the PREVENT Risk Assessment Tool and Visceral Adiposity: Insights from the UK Biobank
AHA Scientific Sessions 2025 abstract3 Nov 2025
Atherosclerotic cardiovascular disease
upin humans1HR 1.32
Visceral adiposity raises the risk of atherosclerotic cardiovascular disease in humans (HR: 1.32, 95% CI: 1.15–1.51).
“higher visceral adiposity (>3.58L) was associated with significantly increased risk of ASCVD (HR: 1.32, 95% CI: 1.15–1.51)”
Humansadjusting for age and sexvisceral adipose tissuen = 38,373
Evaluation of the PREVENT Risk Assessment Tool and Visceral Adiposity: Insights from the UK Biobank
AHA Scientific Sessions 2025 abstract3 Nov 2025
Adding grip strength changed scores for separating risk groups by minus 0.0046 and 0.0045 versus models including detailed body fat and muscle measurements.Adding grip strength changed scores for separating risk groups by minus 0.0046 and 0.0045 versus models including detailed body fat and muscle measurements.
The highest third for pancreatic fat was linked to higher heart failure risk than the lowest third (hazard ratio 1.68, comparing rates over time).The highest third for pancreatic fat was linked to higher heart failure risk than the lowest third (hazard ratio 1.68, comparing rates over time).
A cross-sectional analysis of 59,269 UK Biobank participants found different metabolic associations depending on how fat-free mass was measured and fat around organs.A cross-sectional analysis of 59,269 UK Biobank participants found different metabolic associations depending on how fat-free mass was measured and fat around organs.